Skip to main content
TipRanks
Go Ultimate75% OFF

Avalo Therapeutics (AVTX) Stock Price & Analysis

1,100 Followers

AVTX Stock Chart & Stats

$6.70-$0.43(-6.03%)
At close: 4:00 PM EST
$10$15$20Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$6.68 - $7.18
52-Week Range
$6.53 - $24.27
Previous Close
$7.13
Volume
N/A
Average Volume (3M)
2.65M
Market Cap
$412.28M
Enterprise Value
$453.05M
Total Cash (Recent Filing)
$392.97M
Total Debt (Recent Filing)
$153.00K
Price to Earnings (P/E)
―
Beta
1.50
Next Earnings
Mar 31, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Essentially no reported debt limits near-term interest and refinancing burdens, giving Avalo greater financial flexibility than a similarly loss-making biotech with leverage. This supports continued development spending, although ongoing losses could still require future financing.

Equity Capital Base

The substantial equity base provides a current balance-sheet cushion and reduces dependence on creditors for funding. That support can help sustain clinical programs over the medium term, though the company’s history of equity swings highlights that this strength may depend on financing activity.

Development Pipeline

A focused pipeline across biologic and small-molecule programs gives Avalo multiple potential development paths in immune-mediated and inflammatory diseases. Success could create future product or partnering opportunities, although these candidates remain investigational and are not yet commercial products.

Bears Say

Minimal Revenue

The collapse to roughly $59K of revenue shows that Avalo currently has little recurring commercial activity to support its cost base. This leaves the company dependent on clinical progress and future commercialization or partnering rather than internally generated operating revenue.

Persistent Losses

Large and persistent losses indicate that the current business model is not yet producing earnings power. With expenses vastly above revenue, Avalo has limited capacity to self-fund development, making future financial performance highly dependent on successful pipeline advancement.

Cash Burn And Funding Risk

Sustained negative free cash flow requires external funding to maintain operations, while the new stock-sales agreement provides a mechanism for additional equity financing. Potential issuance can support development but may increase dilution pressure and reflects continuing funding needs.

Avalo Therapeutics News

AVTX FAQ

What was Avalo Therapeutics’s price range in the past 12 months?
Avalo Therapeutics lowest stock price was $6.53 and its highest was $24.27 in the past 12 months.
What is Avalo Therapeutics’s market cap?
Avalo Therapeutics’s market cap is $412.28M.
When is Avalo Therapeutics’s upcoming earnings report date?
Avalo Therapeutics’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 132 days.
How were Avalo Therapeutics’s earnings last quarter?
Avalo Therapeutics released its earnings results on Nov 05, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.588 by $0.248.
Is Avalo Therapeutics overvalued?
According to Wall Street analysts Avalo Therapeutics’s price is currently Undervalued.
Does Avalo Therapeutics pay dividends?
Avalo Therapeutics does not currently pay dividends.
What is Avalo Therapeutics’s EPS estimate?
Avalo Therapeutics’s EPS estimate is -0.45.
How many shares outstanding does Avalo Therapeutics have?
Avalo Therapeutics has 57,823,082 shares outstanding.
What happened to Avalo Therapeutics’s price movement after its last earnings report?
Avalo Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.588. Following the earnings report the stock price went down -6.223%.
Which hedge fund is a major shareholder of Avalo Therapeutics?
Hedge funds hold Avalo Therapeutics shares: the largest hedge-fund position in Avalo Therapeutics is 72,324,437 shares, and hedge funds increased their holdings by 6.6M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology